Interhomolog recombination and loss of heterozygosity in wild-type and Bloom syndrome helicase (BLM)-deficient mammalian cells
Genomic integrity often is compromised in tumor cells, as illustrated by genetic alterations leading to loss of heterozygosity (LOH). One mechanism of LOH is mitotic crossover recombination between homologous chromosomes, potentially initiated by a double-strand break (DSB). To examine LOH associate...
Saved in:
Published in | Proceedings of the National Academy of Sciences - PNAS Vol. 108; no. 29; pp. 11971 - 11976 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
National Academy of Sciences
19.07.2011
National Acad Sciences |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Genomic integrity often is compromised in tumor cells, as illustrated by genetic alterations leading to loss of heterozygosity (LOH). One mechanism of LOH is mitotic crossover recombination between homologous chromosomes, potentially initiated by a double-strand break (DSB). To examine LOH associated with DSB-induced interhomolog recombination, we analyzed recombination events using a reporter in mouse embryonic stem cells derived from F1 hybrid embryos. In this study, we were able to identify LOH events although they occur only rarely in wild-type cells (≤2.5%). The low frequency of LOH during interhomolog recombination suggests that crossing over is rare in wild-type cells. Candidate factors that may suppress crossovers include the RecQ helicase deficient in Bloom syndrome cells (BLM), which is part of a complex that dissolves recombination intermediates. We analyzed interhomolog recombination in BLM-deficient cells and found that, although interhomolog recombination is slightly decreased in the absence of BLM, LOH is increased by fivefold or more, implying significantly increased interhomolog crossing over. These events frequently are associated with a second homologous recombination event, which may be related to the mitotic bivalent structure and/or the cell-cycle stage at which the initiating DSB occurs. |
---|---|
Bibliography: | http://dx.doi.org/10.1073/pnas.1104421108 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 3Present address: Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SA, United Kingdom. Author contributions: J.R.L., J.M.S., and M.J. designed research; J.R.L., J.M.S., J.O., and E.B. performed research; K.Y., K.H., and J.T. contributed new reagents/analytic tools; J.R.L., J.M.S., and M.J. analyzed data; and J.R.L. and M.J. wrote the paper. 1Present address: Department of Human Science, Georgetown University Medical Center, Washington, DC 20057. Edited by James E. Haber, Brandeis University, Waltham, MA, and approved May 20, 2011 (received for review March 22, 2011) 2Present address: Department of Cancer Biology, Beckman Research Institute of the City of Hope, Duarte, CA 91010. |
ISSN: | 0027-8424 1091-6490 |
DOI: | 10.1073/pnas.1104421108 |